更多栏目
搜索
首页 列表页面
百奥泰投资机构群互动实录 | 李胜峰
百奥泰的的创新药和生物类似药如果希望也进入国际市场,已经开始寻求海外合作伙伴了吗?这些产品在中国的价格定位,是否也要考虑中国价格与海外价格的平衡?
READ MORE
会议
礼进生物投资机构群互动实录 | 王结义
假如您需要中美双报,并且做combo的话,在美国PD-1是否会自己一起申报还是和其他已经在美国上市的产品做combo?
READ MORE
会议
董海军:CDMO需要更加完备的研究和开发能力 | 会讯
今年的CPhI研发日CDMO论坛活动将于6月20日在上海举行。
READ MORE
会议
对非小细胞肺癌的新辅助免疫治疗 | AACR会议实录
Neoadjuvant immunotherapy for NSCLC: Is it time to finally stop saving our best for last?
READ MORE
会议
点评:对非小细胞肺癌的新辅助免疫治疗| AACR会议实录
Neoadjuvant immunotherapy for NSCLC: Is it time to finally stop saving our best for last? John V. Heymach MD, PhD
READ MORE
会议
点评:nivolumab+ ipilimumab一线治疗非小细胞肺癌的...
Tumor mutation burden (TMB) as a biomarker for clinical bene t from dual immune checkpoint blockade with nivolumab (nivo)
+ ipilimumab (ipi) in rst-line (1L) non-small cell lung cancer (NSCLC): Identi cation of TMB cuto from CheckMate 568.
READ MORE
会议
nivolumab+ ipilimumab一线治疗非小细胞肺癌的临床疗...
Tumor mutation burden (TMB) as a biomarker for clinical bene t from dual immune checkpoint blockade with nivolumab (nivo)
+ ipilimumab (ipi) in rst-line (1L) non-small cell lung cancer (NSCLC): Identi cation of TMB cuto from CheckMate 568
READ MORE
会议
点评:Nivolumab+ ipilimumab与铂双联化疗(PT-DC)一...
Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as rst-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227
READ MORE
会议
Nivolumab+ ipilimumab与铂双联化疗(PT-DC)一线治疗...
Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as rst-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227
READ MORE
会议
点评:atezolizumab联合贝伐单抗、化疗(chemo)在特...
PFS results for atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) across PD-L1 expression subgroups de ned by the SP142 and SP263 IHC assays con rm all-comer bene t in 1L metastatic NSCLC (mNSCLC)
READ MORE
会议
Copyright © 2016-2020 研发客.All Rights Reserved.
建议反馈: Support@PharmaDJ.com
备案/许可证编号: 沪ICP备17054709号
联系电话:021 - 88194359